PM&R
Volume 1, Issue 7 , Pages 684-686 , July 2009

Rehabilitation in Nephrogenic Systemic Fibrosis

Poster presentation at the Association of Academic Physiatrists, 2008 Annual Assembly, Anaheim, CA, February 19–23, 2008.

  • Larissa Ramaizel, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Department of Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago, Chicago, IL†
    • ,
  • James A. Sliwa, DO

      Affiliations

    • Northwestern University Feinberg School of Medicine, Department of Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago, 345 E. Superior Street, Suite 1509, Chicago, IL 60611‡
    • Corresponding Author InformationAddress correspondence to: J.A.S.

Received 12 February 2009 ,Accepted 19 May 2009.

References 

  1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema like cutaneous diseases in renal dialysis patients [research letter]. Lancet. 2000;356:1000–1001
  2. Cowper SE, Su LD, Phawan J, Robin H, Leboit PE. Nephrogenic fibrosing demopathy. Am J Dermatopathol. 2001;23:383–393
  3. Cowper SE. Nephogenic fibrosing dermopathology: The first 6 years. Curr Opin Rheumatol. 2003;15:785–790
  4. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–572
  5. Ting WW, Stone MS, Madison KC, Durtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903–906
  6. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermapathy). Muscle Nerve. 2004;30:569–577
  7. Jiminez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermapathy). Arthritis Rheum. 2004;50:2660–2666
  8. Kay J. Nephrogenic systemic fibrosis: A gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008;67(Suppl III):iii66–iii69
  9. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  10. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadolinium- associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  11. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis (A mysterious disease in patients with renal failure—role of gadolinium based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate). Clin J Am Soc Nephrol. 2007;2:258–263
  12. Perazella MA. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease. (commentary) Am J Med. 2007;120:561–562
  13. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: Is the stability of the contrast agent molecule an impairment factor in the pathogenesis of this condition?. (commentary) Br J Radiol. 2007;80:73–76
  14. Todd D. Nephrogenic Systemic fibrosis: What nephrologists need to know. Nephrology Rounds. 2007;5:www.hephrologyrounds.orgAccessed June 1, 2009
  15. Distler JN, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311–322

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)00517-6

doi: 10.1016/j.pmrj.2009.05.006

PM&R
Volume 1, Issue 7 , Pages 684-686 , July 2009

Article Tools